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Background
Emergency surgery has become a rare event after percutaneous coronary intervention (PCI). Whether having cardiac-surgery services available on-site is essential for ensuring the best possible outcomes during and after PCI remains uncertain.
Methods
We enrolled patients with indications for nonemergency PCI who presented at hospitals in Massachusetts without on-site cardiac surgery and randomly assigned these patients, in a 3:1 ratio, to undergo PCI at that hospital or at a partner hospital that had cardiac surgery services available. A total of 10 hospitals without on-site cardiac surgery and 7 with on-site cardiac surgery participated. The coprimary end points were the rates of major adverse cardiac events -a composite of death, myocardial infarction, repeat revascularization, or stroke -at 30 days (safety end point) and at 12 months (effectiveness end point). The primary end points were analyzed according to the intention-to-treat principle and were tested with the use of multiplicative noninferiority margins of 1.5 (for safety) and 1.3 (for effectiveness).
Results
A total of 3691 patients were randomly assigned to undergo PCI at a hospital without on-site cardiac surgery (2774 patients) or at a hospital with on-site cardiac surgery (917 patients). The rates of major adverse cardiac events were 9.5% in hospitals without on-site cardiac surgery and 9.4% in hospitals with on-site cardiac surgery at 30 days (relative risk, 1.00; 95% one-sided upper confidence limit, 1.22; P<0.001 for noninferiority) and 17.3% and 17.8%, respectively, at 12 months (relative risk, 0.98; 95% one-sided upper confidence limit, 1.13; P<0.001 for noninferiority). The rates of death, myocardial infarction, repeat revascularization, and stroke (the components of the primary end point) did not differ significantly between the groups at either time point.
2 S ince coronary balloon angioplasty was introduced into clinical practice in 1977, marked advances in technology, technique, adjunctive pharmacotherapy, and operator experience have resulted in higher rates of procedural success and lower rates of complications. 1,2 Emergency coronary-artery bypass grafting (CABG), which was initially required in 6 to 10% of procedures, 1,3 has become a rare event, with an incidence of 0.1 to 0.4% in contemporary studies. [4] [5] [6] Moreover, as data supporting the use of primary PCI for patients with ST-segment elevation myocardial infarction (STEMI) have emerged, the need for timely access to the procedure has justified the expansion of emergency PCI to hospitals that do not have the capability for on-site cardiac surgery. [7] [8] [9] Although there are limited data 10,11 to support the practice of nonemergency PCI at hospitals that do not have the capability for on-site cardiac surgery, there is concern about the ratio of risk to benefit in this setting, as reflected in the class IIb (level of evidence B) recommendation in the 2011 PCI guidelines. 12 The Cardiovascular Patient Outcomes Research Team (CPORT) Non-Primary PCI (CPORT-E) trial, which was reported after publication of the 2011 PCI guidelines, directly compared the outcomes of PCI procedures (excluding primary PCI for STEMI) between hospitals with on-site cardiac surgery and those without on-site cardiac surgery, in a prospective, randomized, controlled trial. 13 PCI performed at hospitals without on-site cardiac surgery was noninferior to PCI performed at hospitals with on-site cardiac surgery with respect to mortality at 6 weeks and the rate of major adverse cardiac events at 9 months.
The Randomized Trial to Compare Percutaneous Coronary Intervention between Massachusetts Hospitals with Cardiac Surgery On-Site and Community Hospitals without Cardiac Surgery On-Site (MASS COMM) was designed in 2006, in collaboration with the Massachusetts Department of Public Health, to provide evidence on which to base regulatory policy decisions about performing nonemergency PCI in hospitals without on-site cardiac surgery. The aim of the trial was to compare the short-term safety and 12-month outcomes of PCI (excluding primary PCI for STEMI) at hospitals without on-site cardiac surgery, as compared with hospitals with on-site cardiac surgery.
Me thods
Study Oversight
MASS COMM was a prospective, multicenter, randomized, controlled, noninferiority trial. The design of the study has been reported previously. 14 The study was designed by the investigators (see the Supplementary Appendix, available with the full text of this article at NEJM.org) and was funded by the participating hospitals without onsite cardiac surgery. The trial was conducted under the principles outlined in the Declaration of Helsinki. The institutional review board at each participating hospital approved the study, and each patient provided written informed consent for participation in the study. The third author and the last author had full access to the data and vouch for the integrity of the analyses presented, and all the authors vouch for the fidelity of this report to the trial protocol, which is available at NEJM.org. The PCI procedures were performed according to the standards of care at each site, and only devices approved by the Food and Drug Administration were used.
Study Participants
We recruited patients who were undergoing diagnostic catheterization for known or suspected coronary artery disease at hospitals without on-site cardiac surgery. To participate in MASS COMM, each hospital that did not have on-site cardiac surgery was required to have approval from the Massachusetts Department of Public Health and to meet minimum requirements for the numbers of PCI procedures performed at the site and by the participating operators. The criteria for participation and for the numbers of PCI procedures performed at the hospital and by the operators are listed in Tables S1 and S2 in the Supplementary Appendix. The key exclusion criteria were a left ventricular ejection fraction of less than 20% and target lesions with any of the following features: unprotected left main coronary-artery stenosis of more than 50% of the luminal diameter, treatment with a procedure other than balloon angioplasty before placement of the stent, a saphenous-vein graft location, or a vessel serving the only viable myocardium 14 (Fig. S1 in the Supplementary Appendix).
Patients were assessed for eligibility and were randomly assigned, in a 3:1 ratio, to undergo PCI 3 at the hospital without on-site cardiac surgery or to be transferred for PCI to a participating hospital with on-site cardiac surgery. Randomization was performed with the use of sealed envelopes, with stratification according to hospital and history or no history of diabetes mellitus.
End Points
The coprimary end points were the incidence of major adverse cardiac events at 30 days (safety end point) and at 12 months (effectiveness end point) after the procedure. The end point of major adverse cardiac events was a composite of death from any cause, myocardial infarction, repeat coronary revascularization, or stroke. Follow-up clinical assessment of the patients was performed in person at 30 days and at 12 months.
Secondary end points included death from any cause, repeat revascularization, stroke, ischemiadriven target-vessel and target-lesion revascularization, definite or probable stent thrombosis (defined according to the Academic Research Consortium criteria), emergency CABG, emergency or urgent PCI, and major vascular complications. 15 Events were adjudicated by an independent clinical events committee, whose members were unaware of the study assignments; the committee was administered by Harvard Clinical Research Institute.
The clinical events committee assessed all lesions in a random sample of 10% of enrolled patients, and the results of their assessment were used in analyses of the proportion of lesions that were treated successfully, the proportion of patients in whom the procedure was successful, the proportion of patients with complete revascularization, and the proportion of lesions that were judged to have met the criteria for class I or II recommendations in the PCI guidelines regarding anatomical indications for PCI. 16 Successful treatment of the lesion was defined as residual stenosis of the target lesion of less than 20%; procedural success was defined as residual stenosis of the target lesion of less than 20% and no occurrence of in-hospital major adverse cardiac events. Complete revascularization was defined as the successful treatment, according to the criteria of procedural success, of all epicardial vessels with more than 70% and less than 100% stenosis. An independent data and safety monitoring board comprised noninvasive and interventional cardiologists and a biostatistician (all residing outside Massachusetts).
Statistical Analysis
The primary end points were compared for noninferiority, whereas all other end points were compared for differences. The noninferiority of hospitals without on-site cardiac surgery as compared with hospitals with on-site surgery with respect to the 30-day rate of major adverse cardiac events (safety analysis) and the 12-month rate of major adverse cardiac events (effectiveness analysis) was assessed with the use of the Farrington-Manning 17 test, with noninferiority margins for relative risk of 1.5 for the safety analysis and 1.3 for the effectiveness analysis. A P value of less than 0.05 for both end points was required to determine noninferiority overall.
Formal noninferiority testing was performed in the intention-to-treat population (all patients who underwent randomization). For patients who missed the 12-month follow-up visit, we obtained data on death from state vital statistics records 18 and successfully linked 99% of the records (see the Supplementary Appendix). For patients with other missing data ( Table S3 in the Supplementary Appendix), we used multiple imputation of major adverse cardiac events before generating the Farrington-Manning one-sided 95% upper confidence interval for relative risk and the noninferiority P value.
With the assumption that the rates of major adverse cardiac events in the two groups would be 6 to 7% at 30 days (safety end point) and 15 to 16% at 12 months (effectiveness end point), we estimated that we would need a sample of 3447 patients who could be evaluated for the study to have 80 to 85% power to show the noninferiority of hospitals without on-site cardiac surgery with respect to the safety end point and 85 to 88% power to show noninferiority with respect to the effectiveness end point. 14, 19 To provide additional statistical power, the original trial design included a cohort of 1200 patients who would be chosen randomly (and who would then provide written informed consent) from the patient pool undergoing routine PCI at the hospitals with on-site cardiac surgery. Because of slow enrollment, recruitment of this cohort was stopped after 164 patients had been enrolled, and the data were not included in the 4 analysis of the primary end point. Calculation of the final sample size assumed that these patients would not be included in the primary analysis. Descriptive comparisons of the 164 patients in this cohort with the first 164 patients who underwent randomization are presented in Tables S4 and S5 in the Supplementary Appendix. In a secondary analysis, we estimated survival free from major adverse cardiac events with the use of the Kaplan-Meier method, and the data are shown according to treatment group in Figures S2 and S3 in the Supplementary Appendix. In another secondary analysis, we accounted for variation among study sites by estimating the between-hospital variance (with standard deviation) and the adjusted relative risks and upper 95% confidence limit for each primary end point, using mixed-model logistic regression, with site considered as a random effect (see the Supplementary Appendix).
Baseline characteristics and secondary end points were compared between the groups with the use of two-sample t-tests for continuous outcomes and chi-square or Fisher's exact tests for dichotomous outcomes; all reported P values are two-sided. Two-sided 95% confidence intervals are reported for percentages based on the normal approximation to the binomial distribution. All statistical analyses were conducted at the Harvard Clinical Research Institute with the use of SAS software, version 9.1.3, with Service Pack 2 (SAS Institute).
R e sult s Participating Sites and Interventionalists
A total of 10 hospitals without on-site cardiac surgery and 7 hospitals with on-site cardiac surgery participated in MASS COMM. Of the 68 operators who participated in the trial, 34 performed PCI at hospitals with on-site cardiac surgery only, and 34 performed procedures at both types of hospitals.
Patients
Between July 7, 2006, and September 29, 2011, a total of 3691 eligible patients were randomly assigned to undergo PCI at a hospital without onsite cardiac surgery (2774 patients) or at a hospital with on-site cardiac surgery (917 patients) (Fig. 1) . A total of 37 patients who underwent randomization did not undergo PCI (13 in the group assigned to hospitals without on-site cardiac surgery and 24 in the group assigned to hospitals with on-site cardiac surgery), and 24 patients (8 and 16 in the two groups, respectively) crossed over and underwent PCI at a site other than the one to which they had been assigned (Fig. S4 in the Supplementary Appendix); the reasons are listed in the Supplementary Appendix. The median follow-up period was 360 days in both groups.
The baseline clinical characteristics were generally similar in the two groups (Table 1) . Angiographic and procedural characteristics reported by the treatment sites are shown in Table 2 . The characteristics of the as-treated population (Tables S6 and S7 in the Supplementary Appendix), in which patients were classified according to the actual treatment received, were similar to those of the intention-to-treat population. The median time from randomization to PCI was 0.1 days in the group assigned to PCI at hospitals without on-site cardiac surgery as compared with 0.6 days in the group assigned to hospitals with on-site cardiac surgery (P<0.001), with 6 patients (0.2%) and 12 patients (1.3%), respectively, undergoing PCI more than 3 days after randomization.
Primary Safety End Point
The rate of major adverse cardiac events at 30 days was 9.5% among patients assigned to undergo PCI at hospitals without on-site cardiac surgery as compared with 9.4% among patients assigned to undergo PCI at hospitals with on-site cardiac surgery (relative risk, 1.00; 95% one-sided upper confidence limit, 1.22; P<0.001 for noninferiority). There were no significant differences between the two groups in the rates of the components of the end point -death from any cause, myocardial infarction, repeat revascularization, and stroke ( Table 3 ). The analysis of the as-treated population showed similar results (Table S8 in the Supplementary Appendix).
Primary Efficacy End Point
The 12-month rates of major adverse cardiac events in the intention-to-treat population were 17.3% in the group assigned to hospitals without on-site cardiac surgery and 17.8% in the group assigned to hospitals with on-site cardiac surgery (relative risk, 0.98; 95% one-sided upper confidence limit, 1.13; P<0.001 for noninferiority) ( Table 3) . Like the safety analysis, the effectiveness analysis showed no significant differences between the two groups in rates of the compo- Nonemergency PCI at Hospitals with or without Cardiac Surgery n engl j med nejm.org 5 nents of the end point -death from any cause, myocardial infarction, repeat revascularization, or stroke. The as-treated analysis showed similar results (Table S8 in the Supplementary Appendix).
Secondary Analyses
Revascularization Procedures
There were no significant differences between the two groups with respect to the rate of emergency CABG or the rate of emergency or urgent PCI at 30 days. The rates of ischemia-driven targetvessel revascularization were also similar in the two groups at 30 days and 12 months (Table 3) .
Treatment Effect Accounting for Between-Hospital Variation
The rate of major adverse cardiac events varied across hospitals by 14 percentage points at 30 days and by 17 percentage points at 12 months ( Fig. S5 and S6 in the Supplementary Appendix). The estimated between-hospital variance components (±SD) were 0.187±0.126 and 0.065±0.060 for the 30-day and 12-month log-odds rates, respectively, of major adverse cardiac events. This translates into a median odds of 1.3, which suggests that the odds of a major adverse cardiac event at 12 months at one randomly selected hospital could be 1.3 times as high as the odds at another randomly selected hospital; at 30 days, the median odds was 1.5. After adjustment for this variation, the relative risks of major adverse cardiac events in the group assigned to hospitals without on-site cardiac surgery, as compared with the group assigned to hospitals with on-site cardiac surgery, were consistent with those of the primary results: a relative risk of 1.02 (95% one-sided upper confidence limit, 1.22) 
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at 30 days and a relative risk of 0.98 (95% onesided upper confidence limit, 1.12) at 12 months.
Angiographic Review Cohort
A total of 376 patients (289 in the group assigned to hospitals without on-site cardiac surgery and 87 in the group assigned to hospitals with on-site cardiac surgery) were randomly selected for blinded angiographic review. There were no significant differences between the two groups with respect to the rates of procedural success, the proportion of patients with complete revascularization, or the proportion of lesions classified as meeting the criteria for class I or II recommendations in the PCI guidelines regarding anatomical indications for PCI (Table 4 ). The as-treated analysis showed similar results (Table S9 in the Supplementary Appendix). * Plus-minus values are means ±SD. There were no significant differences between the groups with the exception of previous myocardial infarction (P = 0.02) and ST-segment elevation myocardial infarction (STEMI) more than 72 hours before PCI of infarct-related or non-infarct-related artery (P = 0.04). CABG denotes coronary-artery bypass grafting, and PCI percutaneous coronary intervention. † Race or ethnic group was self-reported. ‡ Data on the most recent left ventricular ejection fraction were available for 2767 patients in the group assigned to PCI at hospitals without on-site cardiac surgery and 916 in the group assigned to PCI at hospitals with on-site cardiac surgery.
The New England Journal of Medicine Downloaded from nejm.org on March 11, 2013. For personal use only. No other uses without permission.
Copyright © 2013 Massachusetts Medical Society. All rights reserved.
7 * Plus-minus values are means ±SD. The data on characteristics of the procedures and lesions were reported by each site. There were no significant differences between the two groups with respect to these characteristics except for the mean diameter of the reference vessels, the percentage of lesions with Thrombolysis in Myocardial Infarction (TIMI) grade 3 before the procedure, the type of stent (all P<0.001), and the final percentage of lesion stenosis (P = 0.005).
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Discussion
We compared the safety and effectiveness of nonemergency PCI performed at hospitals in Massachusetts without on-site cardiac surgery with those of nonemergency PCI performed at hospitals with on-site cardiac surgery. Hospitals without on-site cardiac surgery were required to have performed a minimum of 300 diagnostic cardiac catheterization procedures per year and to have an ongoing program to support primary PCI. All the operators were required to be board-certified in interventional cardiology and to have performed a minimum of 75 PCI procedures annually. In both the intention-to-treat analysis and the as-treated analysis, we found no significant differences in the coprimary end points of the 30-day and 12-month rates of major adverse cardiac events -a composite of death from any cause, myocardial infarction, repeat revascularization, or stroke -between hospitals without on-site cardiac surgery and those with on-site cardiac surgery. These data now add to the growing body of evidence from single-center experience, 20 registry data, 5,21 and the randomized CPORT-E trial, 13 all of which showed favorable outcomes among patients undergoing elective or nonemergency PCI at hospitals without on-site cardiac surgery. MASS COMM adds to and extends the results of the CPORT-E trial. The blinded angiographic review of a random subgroup of patients allowed for a comparison of clinical practice patterns between the groups. We observed that the practices of lesion selection (according to indications in PCI guidelines), the completeness of revascularization, and procedural success were generally similar, independently of the treatment assignment. Although the rate of use of drug-eluting stents was slightly higher in hospitals with on-site cardiac surgery, this did not translate into differences in the rates of repeat revascularization at 1 year.
We did, however, observe that there was heterogeneity among hospitals within treatment groups with respect to the coprimary end points. Although accounting for between-hospital variation in the primary comparison did not change the overall findings of the study, it does have important implications with respect to monitoring of the performance of individual sites as new PCI programs are initiated.
Expansion of nonemergency PCI to hospitals without on-site surgery may be met with enthusiasm for several reasons. With a larger number of hospitals that can perform the procedure, patients have a wider choice of hospitals and a greater opportunity to remain in their own community. In addition, the added volume of PCI procedures at hospitals without on-site cardiac surgery could help support active primary PCI programs. * A random sample of 350 patients was selected for adjudication of procedure characteristics by a clinical events committee, whose members were unaware of the group assignments. † Successful treatment of the lesion was defined as residual stenosis of the target lesion of less than 20%. ‡ Procedural success was defined as residual stenosis of the target lesion of less than 20% and no occurrence of in-hospital major adverse cardiac events. § Complete revascularization was defined as the successful treatment, according to the criteria of procedural success, of all epicardial vessels with more than 70% and less than 100% stenosis. 
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However, additional issues will need thoughtful consideration. The potential consequence of not having a cardiac surgical team on-site to evaluate the patient and discuss the safest and most effective revascularization strategy when an urgent decision is needed is unclear. Without such a team on-site, the "Heart Team" approach for patients with complex multivessel disease, an approach recommended in the PCI guidelines, 12 is not possible. Moreover, registries generally include only patients who have undergone PCI, and data from patients with coronary artery disease who are not selected for revascularization are limited. Several studies have shown that in patients with STEMI and in those with non-STEMI who do not undergo PCI, treatment according to class I guideline recommendations is provided less often at sites without on-site cardiac surgery than at sites with on-site cardiac surgery. 8, 21, 22 Finally, it is unclear where and by whom interventional cardiology trainees will obtain experience as PCI procedures move from centers with approved training programs to community hospitals.
There are several limitations related to the design and conduct of MASS COMM. Although data were available from more than 97% of the patients at 30 days, data from the 12-month follow-up visit were not available for 13% of the patients. To mitigate the effect of missing data, we performed multiple imputation for the coprimary end-point analysis and ascertained vital status by linking records to state vital statistics data. 23 Furthermore, although the study inclusion criteria were broad, patients with certain clinical and anatomical characteristics were excluded, 14 and thus, the findings in this study should not be generalized to these subgroups. Finally, the study was powered to detect noninferiority with respect to the two coprimary composite end points but was not powered to detect noninferiority with respect to the individual components of the primary end point, such as death or stroke.
In conclusion, nonemergency PCI performed at hospitals in Massachusetts without on-site cardiac surgery was noninferior to PCI performed at hospitals with on-site cardiac surgery with respect to the rate of major adverse cardiac events at 30 days (safety analysis) or at 12 months (effectiveness analysis). These data suggest that performance of PCI in hospitals without on-site cardiac surgery that have established programs for PCI and the requisite experience in performing the procedure, at both the hospital level and the level of individual operators, may be considered an acceptable option for patients presenting to such hospitals for care.
